Immuneering Corp
IMRX
Company Profile
Business description
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
Contact
245 Main Street
Second Floor
CambridgeMA02142
USAT: +1 617 500-8080
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
53
Stocks News & Analysis
stocks
A closer look at US tech earnings
How a handful of tech giants continue to shape market returns and what investors should watch next.
stocks
Cheap ASX energy share lifts earnings guidance on stronger output
Energy provider lifts earnings guidance on stronger power plant performance.
stocks
ASX listed bank overvalued despite strong earnings
Profit beats drive shares higher for Australia’s largest asset manager.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,872.00 | 80.10 | -0.89% |
| CAC 40 | 8,056.38 | 56.19 | -0.69% |
| DAX 40 | 24,350.28 | 11.65 | 0.05% |
| Dow JONES (US) | 49,704.47 | 95.31 | 0.19% |
| FTSE 100 | 10,269.43 | 36.36 | 0.36% |
| HKSE | 26,536.43 | 129.59 | 0.49% |
| NASDAQ | 26,274.13 | 27.05 | 0.10% |
| Nikkei 225 | 62,561.85 | 143.97 | 0.23% |
| NZX 50 Index | 12,995.40 | 215.08 | -1.63% |
| S&P 500 | 7,412.84 | 13.91 | 0.19% |
| S&P/ASX 200 | 8,634.80 | 76.50 | -0.88% |
| SSE Composite Index | 4,222.46 | 2.56 | -0.06% |